Gilead Sciences, whose Kite subsidiary was one of the pioneers of ex vivo cancer cell therapy, is joining the pursuit of in vivo therapies with the acquisition of startup Interius BioTherapeutics. The deal follows AstraZeneca and AbbVie acquisitions this year for in vivo cell therapy developers.
The post Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition appeared first on MedCity News.
